Q32 Bio launched a $55 million private placement issuing 6.7 million shares at $8 per share led by BVF Partners with RA Capital, OrbiMed and Atlas Venture participation. Pro forma cash of $106 million and a first-half-2028 runway propelled an 80% rally to an 18-month high.
Q32 Bio launched a $55 million private placement by issuing 6.7 million common shares at $8 per share, along with pre-funded warrants for 150,000 additional shares. The round was led by BVF Partners, with participation from RA Capital, OrbiMed and Atlas Venture, and Morgan Stanley serving as lead placement agent.
The company held $50.8 million in cash as of March 31, 2026, excluding the new financing. Pro forma cash of approximately $106 million is expected to support operations into the first half of 2028.
Shares jumped over 80% in a single session to their highest level since December 2024, driven by optimism around the autoimmune disease pipeline and institutional backing. The stock is on pace for its strongest monthly performance ever.
